Supplements

Ghrelin Replacement Therapy: Benefits, Evidence, and Realistic Expectations

Ghrelin is often called the 'hunger hormone,' but its role in human physiology runs far deeper than appetite — it regulates growth hormone release, energy balance, and even cardiovascular function. Interest in ghrelin replacement therapy has grown alongside research into peptide-based interventions, yet the clinical picture is more nuanced than headlines suggest. Here's what the evidence actually shows.

Jared Murray ·Co-Founder & Head of Health Research, Ones · ·10 min read
ghrelingrowth hormone secretagoguesipamorelinpeptide therapyhormone optimizationmetabolic health
Ghrelin Replacement Therapy: Benefits, Evidence, and Realistic Expectations

What Is Ghrelin and Why Does It Matter?

Ghrelin is a 28-amino-acid peptide hormone produced primarily in the stomach's oxyntic cells. It was first identified in 1999 by Kojima and colleagues, who discovered it as the endogenous ligand for the growth hormone secretagogue receptor (GHS-R1a). Two distinct forms circulate in the bloodstream: acylated ghrelin (the biologically active form, also called n-octanoyl ghrelin) and des-acyl ghrelin, which lacks the fatty acid modification but still exerts independent physiological effects.

Ghrelin rises sharply before meals and falls after eating — the classic hunger signal. But its functions extend well beyond appetite regulation. Ghrelin stimulates growth hormone (GH) secretion from the pituitary, modulates insulin secretion, influences gastric motility, affects sleep architecture, and plays a role in cardiovascular protection (Kojima et al., Nature 1999; PMID: 10604470). These broad actions are exactly why researchers have explored ghrelin replacement therapy as a potential tool in conditions marked by low ghrelin output or impaired GHS-R signaling.

Who Might Have Low Ghrelin Levels?

Ghrelin levels naturally decline with age and are chronically suppressed in people with obesity — a counterintuitive finding that has fueled debate about whether low ghrelin drives metabolic dysfunction or simply reflects it. Conditions associated with reduced ghrelin include:

  • Post-bariatric surgery states (especially Roux-en-Y gastric bypass, which dramatically lowers fasting ghrelin)
  • Cachexia and anorexia associated with cancer, heart failure, or chronic kidney disease
  • Inflammatory bowel disease
  • Type 2 diabetes with impaired incretin signaling
  • Aging-related GH deficiency

In these contexts, ghrelin replacement or ghrelin receptor agonism has been investigated as a way to restore appetite, preserve lean mass, and support GH pulsatility — all without the side-effect burden of exogenous GH administration.

The Clinical Evidence for Ghrelin Replacement Therapy

The strongest clinical signals for ghrelin replacement come from trials in cachexia and post-surgical recovery. A landmark randomized controlled trial by Temel et al. examined synthetic acylated ghrelin (anamorelin) in cancer cachexia patients; anamorelin significantly improved lean body mass and hand-grip strength compared to placebo over 12 weeks (Temel et al., The Lancet Oncology 2016; PMID: 26698915). These results were compelling enough that anamorelin received approval in Japan for cancer cachexia in 2021.

In the context of cardiac cachexia, a pilot RCT by Nagaya et al. found that intravenous ghrelin infusion in patients with chronic heart failure improved peak workload, left ventricular ejection fraction, and muscle wasting markers over three weeks of twice-daily infusions (Nagaya et al., Circulation 2004; PMID: 15337699). The sample size was small (n=10 per arm), but the mechanistic plausibility is high: ghrelin's vasodilatory and anti-inflammatory properties may directly benefit the failing heart.

For GH secretion, synthetic ghrelin analogs (growth hormone secretagogues, or GHS) consistently amplify GH pulse amplitude. A 2012 systematic review by Garcia et al. in the Journal of Clinical Endocrinology & Metabolism confirmed that GHS compounds reliably increase IGF-1 in GH-deficient and aging adults, though the downstream effects on body composition were more modest than those seen with direct recombinant GH therapy (Garcia et al., JCEM 2012; PMID: 22031519).

It is worth noting that most ghrelin replacement research uses injectable peptide analogs rather than oral ghrelin itself, because native ghrelin has poor oral bioavailability and a short half-life of roughly 30 minutes. This practical limitation shapes realistic expectations: over-the-counter "ghrelin boosters" have an entirely different — and much thinner — evidence base.

Ghrelin vs. Leptin Replacement Therapy: Understanding the Hunger Axis

Ghrelin and leptin are often described as opposites on the appetite regulation axis: ghrelin signals hunger from the stomach, while leptin signals satiety from adipose tissue. Leptin replacement therapy has a longer clinical history, having been approved for the rare condition of congenital leptin deficiency (causing severe early-onset obesity) since the late 1990s with the drug metreleptin.

In people with congenital leptin deficiency, metreleptin produces dramatic reductions in appetite and body weight (Farooqi et al., New England Journal of Medicine 1999; PMID: 10588962). However, leptin replacement in common obesity — where leptin resistance rather than deficiency is the problem — has consistently failed to produce meaningful weight loss. This parallel directly informs ghrelin research: the question is not just whether replacing a hormone changes its circulating level, but whether the downstream receptors remain sensitive.

The same caution applies to ghrelin. In obesity, GHS-R expression appears to be downregulated or desensitized, meaning that simply increasing ghrelin availability may not fully restore its anabolic or appetite-regulating effects. Research into GHS-R sensitization strategies — including caloric restriction, weight loss, and potentially certain phytonutrients — is an active area.

Melatonin Replacement Therapy: A Neighboring Hormone Conversation

When patients research ghrelin replacement, they frequently encounter parallel discussions about melatonin replacement therapy, and for good reason: both hormones share a circadian rhythm dimension. Ghrelin peaks not only pre-meal but also during slow-wave sleep, where it synergizes with the nocturnal GH surge. Melatonin, the pineal gland's darkness signal, helps orchestrate this overnight anabolic window.

Age-related declines in melatonin production — typically beginning in the mid-40s — may attenuate the overnight GH-ghrelin pulse, contributing to the lean mass losses seen in aging. For this reason, some longevity researchers view nighttime melatonin support as a complementary strategy to GHS-based interventions. If you're exploring sleep hormone optimization more broadly, our overview of what melatonin does and what the evidence actually supports covers the clinical nuances in detail.

Melatonin supplementation itself does not replace ghrelin, but it may preserve the sleep architecture (specifically Stage 3 slow-wave sleep) during which endogenous ghrelin-GH coupling is most active. This is an indirect but physiologically meaningful connection.

Estrogen Replacement Therapy and Ghrelin: A Sex-Specific Consideration

One underappreciated dimension of ghrelin biology is its strong interaction with sex hormones. Women consistently show higher circulating ghrelin levels than men at equivalent BMI, and ghrelin falls significantly after menopause — a shift that may contribute to the preferential accumulation of visceral fat seen in postmenopausal women.

Estrogen replacement therapy (ERT) has been shown to partially restore postmenopausal ghrelin levels. A clinical study by Kellokoski et al. found that hormone replacement therapy increased acylated ghrelin concentrations in postmenopausal women, with accompanying improvements in insulin sensitivity (Kellokoski et al., European Journal of Endocrinology 2005; PMID: 15919852). This interaction is clinically relevant: women considering ERT for menopausal symptom relief may also receive indirect ghrelin-related metabolic benefits.

Conversely, women who have undergone surgical menopause without hormone replacement often present with more pronounced GH pulse attenuation than those on ERT. This suggests that for women in this demographic, optimizing estrogen status may be a prerequisite for ghrelin-axis normalization — an argument for a whole-system approach rather than targeting any single hormone in isolation.

Aldosterone Replacement Therapy: Why Hormone Context Matters

Ghrelin does not operate in isolation, and understanding the broader hormonal milieu matters when evaluating any replacement strategy. Aldosterone replacement therapy — typically delivered as fludrocortisone — is used in primary adrenal insufficiency (Addison's disease) and in conditions of mineralocorticoid deficiency causing orthostatic hypotension.

What is the connection to ghrelin? Emerging evidence suggests that the renin-angiotensin-aldosterone system (RAAS) interacts with ghrelin signaling. Ghrelin has been shown to suppress aldosterone secretion in vitro, and patients with primary aldosteronism display altered ghrelin dynamics compared to normotensive controls. While this interaction does not yet translate into a clinical protocol, it underscores the systems-biology principle that hormone replacement decisions — whether for ghrelin, aldosterone, estrogen, or any other endocrine mediator — benefit from a full-panel view of the patient's hormonal landscape.

For individuals with lab-confirmed adrenal axis abnormalities, understanding thyroid antibody patterns alongside adrenal markers can provide important context for how interconnected endocrine signals are.

Ipamorelin, MK-677, and the GHS Landscape

In practice, most people researching ghrelin replacement therapy are actually investigating growth hormone secretagogues (GHS) — compounds that activate GHS-R1a to stimulate endogenous GH release without directly administering GH. The leading research compounds include:

CompoundTypeRouteKey Evidence
AnamorelinGhrelin analogOralPhase III RCTs in cancer cachexia (PMID: 26698915)
IpamorelinSynthetic GHS peptideSubcutaneousGH pulse amplification, favorable safety profile
MK-677 (Ibutamoren)Non-peptide GHSOralSustained IGF-1 elevation over 2 years (Nass et al., JCEM 2008; PMID: 18460560)
GHRP-6Synthetic hexapeptideSubcutaneousEarly GHS research compound; significant appetite stimulation

Ipamorelin is frequently highlighted because it stimulates GH release with minimal effect on cortisol or prolactin — a cleaner hormonal profile than older GHS compounds like GHRP-6. For a deeper look at ipamorelin's evidence base and expected outcomes, see our article on ipamorelin results and evidence-backed benefits.

MK-677 is notable as an orally bioavailable GHS — a rare property in this class. A two-year RCT in healthy older adults found that MK-677 significantly increased IGF-1 and lean body mass, though it also increased appetite and caused a modest rise in fasting glucose (Nass et al., JCEM 2008; PMID: 18460560). This glucose effect is an important safety consideration for anyone with prediabetes or insulin resistance.

Realistic Expectations: What Ghrelin-Axis Interventions Can and Cannot Do

Based on the clinical evidence, here is an honest assessment of what ghrelin replacement therapy and GHS interventions can realistically achieve:

Where the evidence is strongest:

  • Increasing lean body mass in cachectic populations (cancer, heart failure)
  • Stimulating GH pulse amplitude and raising IGF-1 (especially MK-677 and ipamorelin)
  • Improving appetite and caloric intake in medically supervised anorexia or post-surgical states

Where evidence is limited or inconclusive:

  • Fat loss in otherwise healthy, non-cachectic individuals (GH elevation does not reliably translate to meaningful fat loss without caloric restriction)
  • Cognitive or mood benefits (mechanistically plausible via GHS-R1a expression in hippocampus, but no robust clinical trials yet)
  • Longevity extension (animal data are intriguing; human RCT data are absent)

Current regulatory status: Native ghrelin is not approved by the FDA as a drug. Anamorelin is approved in Japan for cancer cachexia. Ipamorelin and MK-677 are classified as research compounds in the US and are not approved for general wellness use. Always consult a qualified healthcare provider before pursuing any peptide therapy.

If metabolic health markers like blood glucose and insulin sensitivity are part of your concern, understanding how to lower A1C without medication or what supplements affect A1C can provide useful context for the broader metabolic picture that GHS research intersects.

What This Means for Your Formula

Ghrelin replacement therapy itself is a pharmaceutical and research-peptide domain — not a supplement category. Ones does not include ghrelin analogs or GHS peptides in its catalog, and for good reason: these compounds require medical supervision, injection protocols, and ongoing lab monitoring that fall outside a supplement framework.

That said, several ingredients in the Ones catalog are directly relevant to supporting the GH-ghrelin axis and the broader anabolic and metabolic functions ghrelin regulates:

  • Ashwagandha (KSM-66, 600mg): A double-blind RCT by Wankhede et al. found that KSM-66 at 600mg daily over 8 weeks significantly increased muscle recovery, testosterone, and reduced cortisol — an important complementary action because chronically elevated cortisol suppresses GH pulsatility (Wankhede et al., Journal of the International Society of Sports Nutrition 2015; PMID: 26609282). By moderating the HPA axis, KSM-66 may preserve the overnight GH-ghrelin window.
  • Zinc: Zinc deficiency is associated with reduced GH receptor sensitivity and lower IGF-1 output. The Ones formula can include zinc at clinically relevant doses, supporting GH-axis signaling at the receptor level.
  • Magnesium Complex (Ones proprietary blend): Magnesium is required for GH secretion and sleep architecture, and deficiency is widespread. Ones' Magnesium Complex is calibrated to avoid the GI burden of cheap magnesium oxide forms.

Ones' AI practitioner evaluates your blood work, wearable sleep data, and health history to determine which combination of these ingredients belongs in your daily capsule formula — calibrated to your specific findings rather than a one-size-fits-all stack.

Key Takeaways

  • Ghrelin is a multifunctional hormone that regulates appetite, GH secretion, energy balance, and cardiovascular function — not simply a hunger signal.
  • The strongest clinical evidence for ghrelin replacement comes from cancer cachexia trials (anamorelin) and cardiac cachexia pilot studies, not from general wellness or fat-loss contexts.
  • Ghrelin, leptin, melatonin, estrogen, and aldosterone are interconnected; targeting any one hormone without understanding the others risks incomplete results.
  • Growth hormone secretagogues like ipamorelin and MK-677 are the practical proxy for ghrelin therapy in most research contexts, but they remain unapproved research compounds in the US.
  • Realistic expectations matter: GHS interventions increase lean mass in deficient or cachectic populations convincingly; fat loss in healthy individuals is a weaker signal.
  • Supplement-based support for the ghrelin-GH axis — through HPA modulation, zinc, and magnesium — is a safer, evidence-informed approach for most people without diagnosed deficiency or cachexia.

This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before starting any hormone therapy or peptide regimen.

Written by Jared Murray, Co-Founder & Head of Health Research, Ones.

Jared is the co-founder and head of health research at Ones, with 25 years applying nutrition science, biomarker interpretation, and clinical supplementation research to individual health programs. He leads the editorial process for the Ones Health Library, where lab data, wearable biometrics, and peer-reviewed clinical research are translated into evidence-based, personalized supplement guidance.

Disclosure: Ones formulates and sells personalized supplements that may include ingredients discussed in this article. We have a financial interest in the products mentioned. Recommendations are based on published research and our editorial standards, not sales targets.

This article is educational content, not medical advice. Consult a healthcare provider before changing your supplement regimen.

Further reading

Related reading